CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed an iteration of CAR-T cell ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.

Luminary Therapeutics today announced that it has been awarded up to $5.8 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...